Please ensure Javascript is enabled for purposes of website accessibility

Johnson & Johnson to Begin Testing a Coronavirus Vaccine in Humans by September

By Keith Speights - Mar 30, 2020 at 9:22AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

J&J's coronavirus vaccine program is moving even faster than the company anticipated.

Johnson & Johnson (JNJ -0.40%) announced Monday that it expects to begin clinical testing in humans evaluating its lead coronavirus vaccine candidate by September 2020 at the latest. It stated earlier this month that it would be November before clinical studies began. The healthcare giant thinks that the first batches of this vaccine could be available for emergency use authorization (EUA) early next year. EUA can be granted by the U.S. Food and Drug Administration (FDA) to make drugs and medical devices available during public health emergencies on a much faster basis than they would be ordinarily.

Moving quickly

J&J's efforts to develop a vaccine protecting against the novel coronavirus disease COVID-19 began in January 2020, after the genetic sequence of the virus was released. The company worked with Harvard Medical School's Beth Israel Deaconess Medical Center to create and test multiple vaccine candidates.

Coronavirus vaccine bottles

Image source: Getty Images.

One key to accelerating this process was the use of J&J's AdVac technology for rapid vaccine development. This technology, along with the company's PER.C6 system for fast, large-scale production of vaccines, was previously used to develop and make its Ebola vaccine and to develop experimental Zika, respiratory syncytial virus (RSV), and HIV vaccine candidates that are currently in clinical testing.

A typical vaccine takes five to seven years of testing before it can be reviewed for regulatory approval. J&J's ability to advance an experimental vaccine from initial discovery into clinical testing to potentially being available for emergency use in early 2021 underscores how quickly the company is moving with its response to the coronavirus.

Others in development

J&J isn't the only drugmaker working on COVID-19 vaccines. Other companies should also move soon into clinical testing, including Inovio and Novavax.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
$171.11 (-0.40%) $0.68
Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
$2.37 (3.95%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.